Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | Non-Final OA | The Regents of the University of California |
| 17931808 | AAV CAPSID VARIANTS | Non-Final OA | California Institute of Technology |
| 17615520 | RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF | Non-Final OA | AMGEN INC. |
| 17845592 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18177068 | LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Non-Final OA | Vanderbilt University |
| 18114923 | METHODS FOR THE TREATMENT OF LUNG TUMORS | Final Rejection | GRADALIS, INC. |
| 18186290 | IN VITRO GENETIC DISEASE MODEL CELL AND METHOD FOR PRODUCING THE SAME | Non-Final OA | RICOH COMPANY, LTD. |
| 17532756 | METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS | Final Rejection | The University of North Carolina at Chapel Hill |
| 17627606 | SIRNA SEQUENCES TARGETING THE EXPRESSION OF HUMAN GENES JAK1 OR JAK3 FOR A THERAPEUTIC USE | Non-Final OA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 17905116 | METHODS AND COMPOSITIONS COMPRISING TRANS-ACTING TRANSLATIONAL ACTIVATORS | Final Rejection | The University of Chicago |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17435365 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | Final Rejection | The Trustees of the University of Pennsylvania |
| 18021901 | DEVELOPMENT OF NOVEL GENE THERAPEUTICS FOR INFLAMMATION-INDUCED BONE LOSS | Final Rejection | University of Massachusetts |
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17596137 | THERAPEUTIC AGENT FOR CANCER | Non-Final OA | OSAKA UNIVERSITY |
| 17432145 | SYSTEM AND METHOD FOR LIGHT-REGULATED OLIGOMERIZATION AND PHASE SEPARATION OF FOLDED DOMAINS AND RNA GRANULE-ASSOCIATED PROTEIN DOMAINS FOR DRUG- BASED SCREENING APPLICATIONS | Final Rejection | The Trustees of Princeton University |
| 17274966 | METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | Fondation Imagine |
| 18320598 | RNA SEQUENCE ADAPTATION | Non-Final OA | CureVac SE |
| 17609691 | MEDIATORS OF GENE SILENCING | Non-Final OA | Cancer Research Technology Limited |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | Non-Final OA | EDITAS MEDICINE, INC. |
| 17426059 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Non-Final OA | KSQ Therapeutics, Inc. |
| 18276061 | Method for Producing Genetically Engineered Cells | Non-Final OA | Cytosurge AG |
| 16973573 | A METHOD OF PRECISION CANCER THERAPY | Final Rejection | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE |
| 17770433 | MICRORNAS ENRICHED IN MEGAKARYOCYTIC EXTRACELLULAR VESICLES AND USES THEREOF | Final Rejection | NATIONAL SCIENCE FOUNDATION |
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | Non-Final OA | Arrowhead Pharmaceuticals, Inc. |
| 18183087 | MUTANT ALGAE, METHOD OF PREPARATION AND APPLICATION THEREOF | Non-Final OA | Reliance Industries Limited |
| 17904641 | DEPLETION OF EXT1 EXPRESSION AND/OR ACTIVITY IMPROVES CELLULAR PRODUCTION OF BIOLOGICAL ENTITIES | Non-Final OA | UNIVERSITÉ DE LIÈGE |
| 17604313 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | Non-Final OA | Buck Institute for Research on Aging |
| 17299278 | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY | Final Rejection | Takeda Pharmaceuticals U.S.A., Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy